aTyr Pharma Inc. Common Stock (ATYR)
Stock · NASDAQ · Health Care
$0.174as of 10/16/2026
Price chart
Active signals
ATYR Signal Track Record
How signals performed across all stocks →What ATYR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | -0.6% | 46% | September 24, 2026 |
| Bollinger Band Breakdown | 22 | -3.2% | 36% | September 1, 2026 |
| Bollinger Band Breakout | 19 | -3.8% | 47% | August 13, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +10.0% | 78% | May 15, 2025 |
| Any 20-session window (baseline) | -1.6% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ATYR
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarc…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 58
- Website
- www.atyrpharma.com/
Fundamentals
- 1-day range
- $0.1842$0.2072
- Market cap
- $49.22M
- P/E (trailing)
- —
- P/E (forward)
- -0.40
- EPS (trailing)
- $-0.80
- Dividend yield
- —
- Beta
- 0.96
- Avg. volume
- 3.28M
How aTyr Pharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
aTyr Pharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ATYRaTyr Pharma Inc. Common Stock$0.174▼ 5.43%Market cap $49.22MP/E —$0.2$1.11
- TILInstil Bio Inc. Common Stock$5.91▼ 3.59%Market cap $49.37MP/E —$5.67$21.64
- TCRXTScan Therapeutics Inc. Common Stock$0.231▼ 3.35%Market cap $49.88MP/E —$0.2243$2.57
- INMBINmune Bio Inc. Common stock$1.57▼ 4.85%Market cap $50.78MP/E —$1.09$2.6
- EXOZeXoZymes Inc. Common Stock$4.09▲ 2.25%Market cap $47.57MP/E —$4.35$18.4
- MGXMetagenomi Therapeutics Inc. Common Stock$0.784▼ 7.22%Market cap $46.68MP/E —$0.86$3.95
- OKYOOKYO Pharma Limited Ordinary Shares$1.41▼ 1.40%Market cap $51.94MP/E —$1.26$3.2
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ATYR aTyr Pharma Inc. Common Stock | $49.22M | — | $0.174 | ▼ 5.43% | $0.2$1.11 |
| TIL Instil Bio Inc. Common Stock | $49.37M | — | $5.91 | ▼ 3.59% | $5.67$21.64 |
| TCRX TScan Therapeutics Inc. Common Stock | $49.88M | — | $0.231 | ▼ 3.35% | $0.2243$2.57 |
| INMB INmune Bio Inc. Common stock | $50.78M | — | $1.57 | ▼ 4.85% | $1.09$2.6 |
| EXOZ eXoZymes Inc. Common Stock | $47.57M | — | $4.09 | ▲ 2.25% | $4.35$18.4 |
| MGX Metagenomi Therapeutics Inc. Common Stock | $46.68M | — | $0.784 | ▼ 7.22% | $0.86$3.95 |
| OKYO OKYO Pharma Limited Ordinary Shares | $51.94M | — | $1.41 | ▼ 1.40% | $1.26$3.2 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- SCHIMMEL PAUL · May 27, 2026 · Buy100.0K @ $0.4963
- Svetlana Lucas · May 11, 2026 · Grant50.0K
- Gross Jane A · May 11, 2026 · Grant50.0K
- BENEVICH ERIC · May 11, 2026 · Grant50.0K
- Zaknoen Sara · May 11, 2026 · Grant50.0K
- Timothy Coughlin · May 11, 2026 · Grant50.0K
- SCHIMMEL PAUL · May 11, 2026 · Grant50.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 55.66M
- Total value held
- $42.03M
- Institutional holders
- 109
- Unknown14.71M
- Unknown10.51M
- Unknown6.44M
- Unknown3.87M
- Unknown3.81M
- Unknown2.39M
- Unknown1.75M
- Unknown1.68M
- Unknown1.64M
- Unknown1.23M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
aTyr Pharma Aligns With FDA On Phase 3 Efzofitimod Plan
aTyr Pharma announced it has reached alignment with the FDA on the protocol for a Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. The company expects to begin study-related activities in the fourth quarter of 2026. This regulatory progress follows a period where the stock traded near its 52-week low, indicating a significant step in the drug's development timeline.
aTyr Pharma Aligns With FDA On Phase 3 Efzofitimod Plan. aTyr Pharma announced it has reached alignment with the FDA on the protocol for a Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. The company expects to begin study-related activities in the fourth quarter of 2026. This regulatory progress follows a period where the stock traded near its 52-week low, indicating a significant step in the drug's development timeline.